Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate ...

New England Biolabs (NEB®) today announces the release of the NEBNext Flu A Integrated Indexing Primer Module (NEB #E3436), ...

In this Q&A, Pratt discusses a recent study comparing multiplex droplet digital PCR (ddPCR) with traditional quantitative PCR ...

Novartis phase III trial for next-generation malaria treatment KLU156 meets primary endpoint, with potential to combat antimalarial resistance: Basel Friday, November 14, 2025, 09 ...

The review also calls for embedding diagnostics within the One Health framework, which integrates human, animal, and ...

Despite strong evidence for metronidazole, amoebiasis persists as a global burden, highlighting gaps in diagnostics and ...

Novartis' GanLum met key Phase 3 goals, showing strong efficacy and safety in malaria patients, including against resistant ...

Novartis (NVS) stock is in focus as the company announces a late-stage trial win for its new malaria drug GanLum developed ...

Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate ...

Using the procedure reported here, all the pipetting steps in LM-PCR can be performed on a Biomek 2000 liquid handling robotic workstation. After thermocycling is completed in the first reaction, the ...

Swiss pharma giant Novartis has announced positive results from KALUMA, a Phase III study for new malaria treatment KLU156 ...

Manning had been listed as questionable on Wednesday, but coach Steve Sarkisian also said his quarterback was practicing and making “good progress” during the week.